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Summary: We examined whether suppression of Oct4 via
RNA interference (RNAi) would affect embryonic stem (ES)
cell lineage choice. Cells were transfected with plasmids
containing an independently expressed reporter gene and
an RNA polymerase type III promoter to constitutively ex-
press small stem-loop RNA transcripts corresponding to
Oct4 mRNA. Cells transfected with Oct4 RNAi constructs
demonstrated reduced levels of Oct4 mRNA and exhibited
characteristics of trophectodermal differentiation. These
findings support the critical role of Oct4 in regulating stem
cell identity and suggest that future experiments using
RNAi in ES cells can elucidate the roles of other genes
affecting lineage specification during differentiation.
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The POU transcription factor Oct4 (encoded by Pou5f1)
has been characterized as a regulator of ES cell pluripo-
tency. Oct4 mRNA and protein are present in the inner
cell mass (ICM) of mouse embryos (Palmieri et al.,
1994), in cultured ES (Rosner et al., 1990), and embry-
onal carcinoma cells (Okamoto et al., 1990), but not in
trophectoderm (Palmieri et al., 1994), or cultured tro-
phoblast stem (TS) cells (Tanaka et al., 1998). Lineage
tracing studies have established that ES cells inserted
into morulae or blastocysts contribute to all tissues of the
fetus but not the trophectoderm or primitive endoderm
(Beddington and Robertson, 1989), whereas TS cells are
conversely restricted to the trophoblast lineage (Tanaka
et al., 1998). However, genetic studies have shown that
altering expression levels of Oct4 can modify the early
lineage restriction of ICM/ES cells. For example, Oct4-
deficient embryos fail to form an ICM but instead consist
primarily of cells committed to the trophoblast lineage
(Nichols et al., 1998), and gene-targeted ES cells express-
ing reduced levels of Oct4 differentiate to trophecto-
derm in vitro while overexpression induces differentia-
tion into primitive endoderm and mesoderm (Niwa et
al., 2000). As a means of exploring the Oct4-mediated
plasticity of ES cells (and with the understanding that the
endogenous Pou5f1 locus likely has regulatory roles for
other transcription factors), we wished to determine
both the efficacy and the developmental consequences
of knocking down Oct4 expression in wildtype ES cells
posttranscriptionally via RNA interference (RNAi).
RNAi is a widely used tool for suppressing gene ex-
pression in invertebrates and plants, but its application
in mammals has been hindered until recently because
the introduction of double-stranded RNA (dsRNA) longer
than about 30 basepairs induced a presumably antiviral
“interferon response” of nonspecific gene suppression
(Zamore, 2001). Transfection of 30 bp dsRNA into
undifferentiated mouse ES cells was reported to sup-
press function of a transgene in an RNAi-like manner,
suggesting ES cells lack the interferon response (Yang et
al., 2001), but the possibility remains that, with differ-
entiation, gene suppression could become nonspecific.
However, it has now been shown that the interferon
response can be circumvented altogether in differenti-
ated mammalian cells through the use of short (30 bp)
interfering RNA duplexes (siRNAs) (Elbashir et al.,
2001). Moreover, siRNAs have been produced constitu-
tively in mammalian cells using vectors containing RNA
polymerase type III promoters such as the U6 small
nuclear RNA promoter (U6) (Yu et al., 2002; Paul et al.,
2002) or H1 promoter (Brummelkamp et al., 2002) driv-
ing expression of a single RNA transcript that folds into
a hairpin siRNA. It has recently been shown that knock-
down of p120-Ras GTPase-activating protein via hairpin
siRNAs driven from the H1 promoter could recapitulate
a Rasa1 null phenotype in ES cell-derived embryos (Ku-
nath et al., 2003). In each instance, significant reduction
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in the expression of targeted genes in a sequence-spe-
cific manner was observed and, because the siRNAs
were constitutively expressed, long-term gene suppres-
sion could be achieved.
In designing our siRNA expression vectors, it was not
known if the U6 or H1 promoters would exhibit any
differences in activity in ES cells as it has been reported
that different Pol III promoters can show variations in
the level and localization of transcript expression (Ilves
et al., 1996). To test this, we transfected B5 mouse ES
cells expressing an enhanced green fluorescent protein
(eGFP) transgene (Hadjantonakis et al., 1998) with plas-
mids (Fig. 1a) containing either U6 or H1 hairpin siRNA
expression cassettes with coding sequences correspond-
ing to eGFP mRNA (pU-eGFPi and pH-eGFPi, respectively).
Cells transfected with either eGFPi plasmid showed signif-
icantly reduced levels of eGFP protein and mRNA when
assayed at 48 and 72 h posttransfection as compared to
controls transfected with the pBluescript II SK parent plas-
mid (pSK) alone (Fig. 2, Table 1), and we noted that cell
cultures transfected with pH-eGFPi contained significantly
more eGFP-negative cells after 72 h as compared to any
other treatment group (Table 1). Overall, these results
indicated that constitutively expressed hairpin siRNAs
could effectively suppress gene expression in ES cells and
that the H1 promoter appeared to be slightly more effec-
tive at maintaining hairpin siRNA-mediated RNAi. We then
wished to determine whether RNAi targeting of an endog-
enous regulatory gene such as Oct4 would have conse-
quences in lineage segregation or developmental potential.
To identify transfected cells, pRed expression con-
structs (Fig. 1b,c) were made in which a red fluorescent
protein (DsRed) is driven from the simian cytomegalovi-
rus immediate-early enhancer/promoter in the pCS2 vec-
tor (Turner and Weintraub, 1994). In the second multi-
ple cloning site we placed either U6 or H1 hairpin siRNA
expression cassettes containing coding sequences corre-
sponding to Oct4 mRNA (pCU-Octi and pCH-Octi, re-
spectively). D3 mouse ES cells were transfected with
pCU-Octi, pCH-Octi, or pRed alone (day 0), cultured in
ES cell medium supplemented with leukemia inhibitory
factor (LIF) to inhibit differentiation (Williams et al.,
1988), then enriched by fluorescence activated cell sort-
ing (FACS) based on expression of DsRed on day 1.5. At
1, 3, 5, or 7 days after transfection, cells were fixed for
immunohistochemical analysis and RNA isolated from
cell lysates for RT-PCR assays.
As shown in Figure 3, cells transfected with pRed (Fig.
3e–g) were similar to untransfected ES cells, having a
high nucleus:cytoplasm ratio and multiple nucleoli typ-
ical of ES cells. In contrast, many cells transfected with
either pCU-Octi (Fig. 3h–j) or pCH-Octi (Fig. 3k–m) were
morphologically similar to trophoblast giant cells (epi-
thelioid cells with large nuclei and dark perinuclear
deposits) (Tanaka et al., 1998). When viewed with the
scanning electron microscope, wildtype D3 ES cells (Fig.
3a) were compact, with filopodia but few lamellipodia.
In contrast, the trophoblast-like cells (Fig. 3b) were
highly spread, exhibiting a large nuclear bulge and an
expansive cytoplasm that frequently surrounded neigh-
boring cells. Immunostaining showed that the tropho-
blast-like cells in the experimental groups expressed a
trophectodermal marker, TROMA-I (Hashido et al.,
FIG. 1. Hairpin siRNA and DsRed expression constructs. a: Dia-
gram of U6 and H1 RNA Pol III promoter-based hairpin siRNA
expression vectors used to target eGFP in B5 ES cells. The U6 or H1
promoter has been cloned into pSK plasmids with an engineered
BglII site at position –9 to –4. Templates encoding hairpin siRNAs
with 19-nt of homology to the eGFP transgene were synthesized as
64-mer DNA oligonucleotides, annealed in vitro, and inserted as
shown. Base pairing between sense and antisense strands of the
transcript is predicted to produce a hairpin siRNA with a 9-nt loop.
b: The pRed vector contains a red fluorescent reporter (DsRed2)
with an SV40 polyA signal sequence driven from the constitutively
active simian cytomegalovirus immediate-early RNA Pol II enhancer/
promoter. c: Oct4 RNAi reporter constructs contain the DsRed reporter
and either a U6 or H1-based RNAi cassette in the opposite orientation.
Pol II transcription from the CMV promoter (right arrow) produces
DsRed, whereas Pol III transcription from U6 or H1 (left arrow) pro-
duces hairpin siRNAs targeting Oct4. d: “Mutant” Oct4 RNAi (mOcti)
constructs are identical to the Octi constructs tested except for a 2-nt
substitution (underlined) in the middle of the hairpin stem.
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1991) (Fig. 3j,m), whereas pRed-transfected cells were
consistently TROMA-I negative (Fig. 3g). It should be
noted that in both the pCU-Octi and pCH-Octi treated
groups, the sorted cell populations initially were 90–
95% pure (data not shown). However, the small fraction
of untransfected cells not eliminated by FACS expanded
significantly in culture by d5 and 7, likely due to the
favorable conditions imparted by the culture medium.
The presence of untransfected cells had an interesting
effect in the experimental groups in that we observed
several instances where the Octi-treated cells sur-
rounded untransfected cells in a manner reminiscent of
a blastocyst (Fig. 3c,d). That is, we frequently saw clus-
ters of untransfected ES cells completely or partially
enveloped (as in Fig. 3h–m) by transfected trophecto-
derm-like cells.
We used RT-PCR to assay for expression of Oct4
mRNA and one of its downstream target genes, Fgf4
(Nichols et al., 1998), as well as markers of proliferating
trophoblast, mEomes (Russ et al., 2000) and Fgfr2 (Orr-
Urtreger et al., 1993), and trophoblast giant cells, Pl-I
(Faria et al., 1991). As shown in Figure 4, we detected
FIG. 2. Suppression of eGFP via RNAi. a: B5 ES cells 72 h after
electroporation with control plasmid, pSK, show little to no loss of
eGFP expression. b,c: B5 ES cells 72 h after electroporation with
either pH-eGFPi (b) or pU-eGFPi (c) show a significant reduction in
the number of eGFP-positive cells and the clonal distribution pattern
observed suggests that the eGFP suppression is stable and herita-
ble. A detailed statistical analysis indicated that pH-eGFPi was
slightly more effective in suppressing eGFP fluorescence than
pU-eGFPi at 72 h. d: RT-PCR analysis shows reduced levels of
eGFP mRNA at 48 and 72 h in cells electroporated with either eGFP
RNAi construct as compared to the control group at 72 h.
Table 1
eGFP Expression in B5 ES Following Treatment With
eGFPi or Control Plasmids
Treatment group eGFP cells eGFP cells
48h, 72h pSK 2054 80
48h, 72h pU-eGFPi 2437* 854*
48h pH-eGFPi 1261* 582*
72h pH-eGFPi 1267* 874*
*P  0.001, eGFPi vs. pSK.
FIG. 3. Suppression of Oct4 via RNAi induces trophectodermal
differentiation in wildtype ES cells. a,b: When viewed with an SEM,
cultures of D3 ES cells transfected with control plasmid (a) exhibit a
typical ES cell morphology and contain only compact clusters of
cells with filopodia and few lamellipodia. In contrast, cultures of cells
transfected with either pCU-Octi (b) or pCH-Octi (not shown) con-
tain very large epithelioid cells with features characteristic of tro-
phoblast giant cells such as an extensive, thinly spread cytoplasm
(boundary indicated by arrowheads) and a pronounced nuclear
bulge (arrow). c,d: Live-cell phase contrast (c), and epifluorescence
microscopy (d) images of cells transfected with pCH-Octi and en-
riched by FACS show the presence of untransfected, DsRed-neg-
ative cells (arrow) that retain an ES cell morphology. The Octi-
transfected cells, however, appear more epithelioid and surround
the clusters of ES cells in a manner reminiscent of a “blastocyst.”
e–m: D3 ES cells transfected with pRed alone (f) retain an ES cell
morphology (e) and do not react with the trophoblast giant cell-
specific antibody, TROMA-I (g). Cells transfected with pCU-Octi
(h–j) or pCH-Octi (k–m) change their ES cell morphology as they
differentiate into large, flattened cells exhibiting characteristics of
trophoblast giant cells such as large nuclei, extensive cytoplasmic
spreading, dark perinuclear deposits (h,k) and TROMA-I immuno-
staining (j,m). Panels h–m show other examples in which the trans-
fected trophectoderm-like cells can be seen enveloping untrans-
fected ES cells (arrows). Scale bars in a–m  100 m.
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upregulation of early trophoblast markers by d1
(mEomes) and d3 (Fgfr2) and a later marker for tropho-
blast giant cells (Pl-I) by d5 in the experimental groups,
consistent with the trophectodermal phenotype ob-
served in our morphological analyses. Other lineage-
restricted genes such as Sox2 (neuroectoderm) and
Brachyury (mesoderm) were not expressed in the Octi
treatment groups (data not shown), further indicating
that the differentiation induced by Oct4 RNAi was tro-
phoblast-specific. Reduced expression of Oct4 and Fgf4
was only slightly apparent at d1 (prior to sorting), pre-
sumably due to the large number of untransfected cells
present that were still expressing these markers in the
unsorted cultures. Purification of the cultures by FACS
and subsequent analysis indicated an abrogation of Oct4
and Fgf4 mRNA in both experimental groups at d3.
However, we saw a slight increase in Oct4 and Fgf4
expression at d5 and d7, presumably due to the expan-
sion of untransfected ES cells that remained in each
culture, as discussed above.
While the increase in Oct4 and Fgf4 in the Octi cul-
tures could be attributed to expansion of the untrans-
fected ES cells not eliminated by FACS, the possibility
remains that the suppression of Oct4 was transient or
incomplete. In order to assess Oct4 expression at the
protein level in individual cells, we performed additional
transfections followed by immunohistochemical analy-
ses using TROMA-I and Oct4-specific antibodies. In ad-
dition, although RNAi has been reported to be highly
sequence-specific (Brummelkamp et al., 2002; Yu et al.,
2002), we reasoned that the effects observed in our
previous experiments could have been a generic re-
sponse of the cells to hairpin siRNAs, so we also trans-
fected cells with pCU-mOcti and pCH-mOcti constructs
(Fig. 1d) containing a 2-nucleotide “mutation” in the
middle of the hairpin stem as an additional control. Cells
were transfected with either control or Octi constructs,
cultured for 1 day, plated at low density (150 cells
mm-2), and allowed to grow for an additional 2–4 days.
The cultures were not sorted by FACS so that untrans-
fected Oct4 ES cells would remain as internal positive
controls for the Oct4 antibody.
We assayed the cells at 1, 3, or 5 days following
transfection and found that cells transfected with either
mOcti (Fig. 5a) or pRed constructs (not shown) exhib-
ited normal nuclear expression of Oct4 protein as indi-
cated by Hoechst 33258 co-staining (not shown) after 1
day as compared to untransfected cells. In contrast, cells
FIG. 4. Changes in gene expression patterns following suppression
of Oct4 via RNAi. RT-PCR analyses of RNA isolated from cell lysates
illustrates the abrogation of Oct4 mRNA transcripts and suppres-
sion of a downstream target gene, Fgf4, in cells transfected with
either pCU-Octi or pCH-Octi. Concomitant with the suppression of
Oct4 and Fgf4, the upregulation of early trophoblast markers,
mEomes and Fgfr2, is observed by d3 in the Octi treatment groups,
while expression of a late trophoblast marker, Pl-I, is not observed
until d5. Cells transfected with control plasmid (pRed) show no
reduction in Oct4 or Fgf4 nor upregulation of any trophoblast mark-
ers at any time point assayed. Cells were sorted 1.5 days after
transfection; thus, d1 lanes represent data from mixed cultures,
whereas d3, d5, and d7 lanes represent enriched (sorted) cultures.
The expression of Oct4 and Fgf4 observed in the Octi treatment
groups at d5 and d7 is likely due to the proliferation of untransfected
ES cells that were not excluded by FACS (see text for details).
Analyses of lysates from undifferentiated D3 ES cells (D3), day 13
mouse embryos (d13), and day 9 mouse placenta (Pl) all show
appropriate expression levels of the markers tested. Expression of
-actin is included as a positive control.
FIG. 5. Knockdown of Oct4 by hairpin siRNA constructs is se-
quence-specific. a,b: Merged images illustrating the expression of
Oct4 (green) and DsRed (red) in unsorted D3 ES cell cultures 24 h
after treatment with control (a) or Octi (b) constructs. Untransfected
(DsRed-) ES cells present in both cultures show nuclear expression
of Oct4 confirmed by Hoechst 33258 co-staining (not shown). Cells
transfected with pCU-mOcti (a) also show nuclear expression of
Oct4 (yellow), whereas cells transfected with pCU-Octi (red cells in
b) are Oct4-. c–f: Merged images showing the expression of Oct4
(blue) and either DsRed (red in c,d) or TROMA-I (green in e,f) in
unsorted D3 ES cell cultures 5 days after treatment with control (c,e)
or Octi (d,f) constructs. Cells transfected with pCH-mOcti (red cells
in c) coexpress Oct4 and do not exhibit any immunoreactivity to
TROMA-I (e). In contrast, cells transfected with pCH-Octi (red cells
in d) are Oct4- and exhibit overt signs of trophectodermal differen-
tiation, including TROMA-I immunoreactivity (f). Scale bars in a–f 
100 m.
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transfected with either pCH-Octi (Fig. 5b) or pCU-Octi
(not shown) constructs were noticeably devoid of Oct4
protein within 1 day of treatment. We did not observe
TROMA-I cells in any of the d1 cultures (not shown),
but this might be expected, given that it is a marker of
differentiated trophoblast giant cells. By day 5, however,
95% of the Octi-transfected cells we observed were
Oct4- (Fig. 5d,f) and TROMA-I (Fig. 5f), whereas cells in
the control groups remained Oct4 (Fig. 5c, e) and
TROMA-I- (Fig. 5e). To quantify these observations, we
carried out cell counts (Table 2) of transfected (DsRed)
cells based on Oct4 and TROMA-I immunoreactivity in
10 randomly selected fields from three replicate samples.
We did not observe any statistically significant variation
(P  0.05) between the control groups (pRed, pCU-
mOcti, and pCH-mOcti) at each time point, indicating
that the effects of transfection with either mOcti con-
struct were no different than treatment with the pRed
construct alone. Similarly, no significant differences (P 
0.05) were observed between the U-Octi and H-Octi
groups at each time point. However, significant (P 
0.001) differences were observed when comparing the
controls versus the Octi groups at any of the time points.
In addition, when we performed multiple comparisons
between each control and Octi group, we also observed
differences in the populations between time points. That
is, the Octi treatment groups were significantly different
from each other (P  0.001) at d1, d3, and d5, probably
a reflection of the temporal delay between suppression
of Oct4 and development of TROMA-I immunoreactivity.
The control groups also differed significantly when com-
paring d1 versus d3 and d1 versus d5 (P  0.001) but not
d3 versus d5 (P  0.99), most likely due to random
differentiation occurring as a result of low-density cul-
ture (Robertson, 1987).
Our results indicate that expression vectors contain-
ing either U6 or H1 RNA Pol III promoters can be used
to generate hairpin siRNAs that effectively and rapidly
suppress gene expression in ES cells in a sequence-
specific manner. Whereas most vector-based RNAi stud-
ies to date have used U6 or H1 promoters exclusively,
we have considered the possibility that these promoters
exhibit different levels of activity in ES cells. The clearest
differences are observed in our eGFPi experiments (Ta-
ble 1); however, we also see subtle variations in the Octi
data as well. For example, the RT-PCR data in Figure 4
reveal slight differences between the U6 and H1 vectors
in both the suppression of Oct4 and Fgf4 (d7 lanes) and
induction of early (Fgfr2) and late (Pl-I) trophoblast
genes (d3, d5, and d7 lanes). In the Octi experiments
(Table 2), there were fewer Oct4 cells in the H-Octi
treatment groups at d3 and d5 compared to the U-Octi
group, although these differences were not statistically
significant (P  0.16 for d3; P  0.11 for d5). Taken
together, our data suggest that H1-mediated RNAi ap-
pears to be more effective at suppressing gene expres-
sion compared to the U6 promoter. Recent studies com-
paring U6 and H1-mediated RNAi knockdown of VEGF in
cultured cells have observed similar (although not statis-
tically significant) differences in overall efficacy (Zhang
et al., 2003). While it is possible that the differences
observed merely reflect variations in transfection and/or
integration efficiency as has been proposed (Zhang et
al., 2003), we believe our findings suggest the need for
more rigorous quantitative analysis of the relative activ-
ities of these promoters in vector-based RNAi applica-
tions.
We have also shown that RNAi-mediated suppression
of a developmentally relevant gene such as Oct4 has
significant effects on lineage choice and plasticity in
wildtype ES cells and induces differentiation even in the
presence of serum and LIF, inhibitors of ES cell differen-
tiation. The fact that we observe trophectodermal differ-
entiation further supports an emerging model of devel-
opmental plasticity whereby stem cells may be capable
of undergoing “de-differentiation” to a more primitive
lineage, thus acquiring fates from which they were orig-
inally thought to be restricted (Rossant, 2001; Hübner et
al., 2003). Recent work has shown that human ES cells
are similarly capable of dedifferentiation to the tropho-
blast lineage when treated with bone morphogenetic
protein 4 (Xu et al., 2002). In this context, RNAi appears
to be a valuable tool in stem cell biology for dissecting
the pathways involved in lineage segregation. Hairpin
siRNA expression vectors should also be useful for de-
velopmental studies in vivo, as it has been recently
demonstrated that expression vectors (including those
for hairpin siRNAs) can be injected into the tail vein of a
Table 2
Oct4 and TROMA-I Expression Profiles of ES Cells Transfected With Octi or Control Plasmids
Treatment group Oct4 TROMA-I Oct4/TROMA-I Total red cells
Day 1: Controls 631 0 0 631
U-Octi 10* 0 191* 201
H-Octi 9* 0 226* 235
Day 3: Controls 524 0 30 554
U-Octi 8* 57* 27* 92
H-Octi 4* 53* 35* 92
Day 5: Controls 546 0 34 580
U-Octi 4* 56* 6* 66
H-Octi 1* 76* 4* 81
*P  0.001, Octi vs. controls.
All TROMA-I cells were Oct4; conversely, all Oct4 cells were TROMA-I.
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pregnant mouse and delivered to the developing embryo
(Gratsch et al., 2003). Numerous developmental studies
have taken advantage of inducible or tissue-specific pro-
moter systems to elucidate the effects of extrinsic and
intrinsic cell signals in development. We believe that
conditionally expressed hairpin siRNAs could be used in
a similar manner to address the effects of a specific gene
product during particular stages of embryogenesis or
differentiation of ES cells as embryoid bodies.
MATERIALS AND METHODS
Plasmid Construction
Mouse U6 and H1 promoters were PCR-amplified from
sv129 mouse genomic DNA, digested with EcoRI and
BamHI and cloned into pBluescript II SK (pSK) phage-
mids (Stratagene, La Jolla, CA) to make the subclones
pU6 and pH1. Hairpin siRNA templates corresponding to
nt 1325–1341 of pEGFP-N1 (ClonTech, Palo Alto, CA)
were designed as previously described (Brummelkamp
et al., 2002), synthesized as DNA oligonucleotides, an-
nealed in vitro as described (Yu et al., 2002), and ligated
within the BglII and NotI sites of pU6 or pH1 to make
pU-eGFPi and pH-eGFPi. The red fluorescent protein,
DsRed2, was PCR amplified from pDsRed2-1 (Clon-
Tech), digested with BamHI and XbaI, and cloned into
pCS2 (provided by David Turner) to make pRed. The
U6 and H1 promoters were released from pU6 and pH1
by digestion with KpnI and NotI and moved into the
corresponding sites of pRed to give the subclones, pCU
and pCH. Hairpin siRNA templates corresponding to nt
670–688 of Oct4 (GenBank X52437) were inserted into
pCU or pCH digested with BglII and NotI to construct
pCU-Octi and pCH-Octi. DNA oligonucleotide templates
with “mutations” corresponding to an AG3CA substitu-
tion at nt 678–679 in the Oct4 open reading frame were
similarly inserted into pCU or pCH to produce pCU-
mOcti and pCH-mOcti. Sequences for PCR primers and
DNA oligonucleotide templates used in plasmid con-
struction are provided in the on-line supplementary ma-
terial.
Cell Culture, Transfection, and FACS
B5 and D3 mouse ES cells were cultured on 0.1%
gelatin-coated substrates in ES medium consisting of
DMEM (Invitrogen, Carlsbad, CA) supplemented with
10% ES-tested FBS (Atlanta Biologicals, Norcross, GA),
10-4M -mercaptoethanol (Sigma, St. Louis, MO), 0.224
g/ml L-glutamine (Invitrogen), 1.33 g ml-1 HEPES (In-
vitrogen), and 1,000 units ml-1 human recombinant LIF
(Oncogene Research Products, San Diego, CA). 1.5 	
106 B5 ES cells suspended in 800 l of ES medium were
electroporated with 20 g of NotI-linearized plasmid
(pSK, pU-eGFPi, or pR-eGFPi) using a BioRad (Hercules,
CA) Genepulser (0.3 kv current, 250 F capacitance)
and seeded onto six-well plates at 2.5 	 105 cells per
well. For the Oct4 RNAi studies, wildtype D3 mouse ES
cells were seeded onto six-well plates at 7.5 	 105 cells
per well and transfected with 1 g DNA/well (pRed,
pCU-Octi, or pCR-Octi) 24 h later using Lipofectamine/
Plus Reagent (Invitrogen) in serum-free DMEM. After 3 h,
the transfection medium was replaced with ES medium;
we designated this timepoint as d 0. At d 1.5, cells were
dissociated with 0.25% trypsin/1mM EDTA, resuspended
in PBS, and sorted based on expression of DsRed2 with
a Coulter Elite ESP Cell Sorter using a 514 nm argon laser
excitation source and 575 nm bandpass filter. Suspen-
sions of the sorted cells were gently added to gelatin-
coated 35 mm dishes or 13 mm diameter Thermanox
coverslips (Nalge Nunc Intl., Rochester, NY) at a density
of 150 cells mm-2 and then cultured up to d 7 in ES
medium containing 100 units ml-1 penicillin and 100 g
ml-1 streptomycin.
Microscopy and Immunohistochemistry
All light microscopy was performed on a Leitz Flou-
vert microscope equipped for phase contrast and epiflu-
orescence microscopy and outfitted with a Nikon
DXM1200 digital camera. Images were captured using
Nikon ACT-1 digital imaging software and then imported
into PhotoShop 6.0 (Adobe Systems, San Jose, CA) to
compose the figures. For the eGFP RNAi studies, live B5
ES cells were imaged 48 and 72 h following transfection
using a combination of low-light phase contrast and
eGFP epifluorescence. For the Oct4 RNAi studies, live-
cell phase contrast and DsRed epifluorescence micros-
copy was performed at 24-h intervals to track general
changes in cell morphology, DsRed2 expression, and
cell number. At the time-points assayed, cells were fixed
with 2% paraformaldehyde/PBS, washed, and stored at
4°C in PBS. Nonspecific antibody binding was blocked
by incubating in 10% donkey serum, then cells exposed
to anti-cytokeratin endoA (TROMA-I ascites, Develop-
mental Studies Hybridoma Bank, U. of Iowa, 1:50) and
Oct4 antibody (sc-8628, Santa Cruz Biotechnology, Santa
Cruz, CA, 1:100), followed by appropriate secondary
antibodies conjugated to FITC (TROMA-I) or AMCA
(Oct4). To confirm nuclear localization of Oct4 protein,
selected samples were stained with Hoechst 33258
(Sigma). In these samples, the secondary antibodies
were reversed (AMCA:TROMA-I; FITC:Oct4) since the
cytoplasmic signal from TROMA-I could be clearly dis-
cerned from the Hoechst nuclear stain. For statistical
analyses, cell counts were obtained from at least 10
randomly selected fields (25	 objective) of treatment
and control groups at each time point indicated and the
data entered into Microsoft Excel spreadsheets for Chi-
square statistical analysis (with Yates and Bonferroni
inequality corrections where appropriate). For SEM anal-
ysis, cells grown on Thermanox coverslips were fixed in
2% glutaraldehyde / 0.1M Sorensen’s phosphate buffer,
then postfixed in 1% OsO4/0.1M Sorensen’s phosphate
buffer. Samples were dehydrated through a graded eth-
anol series, rinsed twice with hexamethyldisilazane, and
air-dried. Specimens were mounted on conductive stubs,
sputter-coated with Au-Pd, and viewed with an Amray
1000B SEM (10 keV) equipped with a SEMICAPS
SEMSYNC digital imaging system.
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RT-PCR
Cytoplasmic RNAs were extracted from lysates of cells
treated with TRIzol reagent (Invitrogen), DNAsed, and
quantified by spectrophotometry. For the eGFP RNAi
studies, cell lysates were collected 48 and 72 h after
electroporation. For the Oct-4 RNAi studies, lysates were
collected at 1, 3, 5, and 7 days after transfection. RNAs
isolated from untreated D3 ES cultures, gestation day 13
mouse embryos, and gestation day 9 mouse placental
tissue were included as additional controls. RNAs (1 g
each) served as templates in reverse transcription reac-
tions with oligo-dT primers, and 1/20 of the single-strand
cDNA products were used in each PCR amplification.
General PCR conditions were 94°C / 3 min,
94° / 30 s, 53–63°C / 1 min, 72°C / 1 min for 25–40
cycles. Specific information regarding PCR primer se-
quences and reaction conditions is provided in the on-
line supplementary material. The PCR products (10 l
each) were electrophoresed in 1.5% agarose gels in the
presence of ethidium bromide, then photographed in a
UV light box.
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